 AUSTIN, Texas, Dec. 15, 2020 GLOBE NEWSWIRE -- P lus Therapeutics, Inc. Nasdaq: PSTV the Company, a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECTTM Phase 1 clinical trial evaluating the Companys lead investigational asset, Rhenium NanoLiposome RNLTM, in patients with recurrent glioblastoma GBM. 